Outsourced Pharma Capacity Update Videos - Cell & Gene
-
FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Cell & Gene Therapy
4/24/2025
Director of Commercial Development, Serat Ali, describes FDBs' Advanced Therapy capabilities, discusses their global facilities network, and provides a capacity update.
-
Vinta Bio Capacity Update April 2025: Cell & Gene Therapy
4/24/2025
Uncover how an intensified adherent AAV manufacturing process is unlocking high-yield, low-impurity clinical production with over 95% full capsids in a streamlined, compact platform.
-
Kincell Bio Capacity Update April 2025: Cell & Gene Therapy
4/24/2025
Explore how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies.
-
Capacity Update April 2025: Cell & Gene Therapy
4/24/2025
Witness how NYBCe and CCS are transforming cell and gene therapy development with end-to-end CDMO solutions, advanced logistics, and a growing innovation hub in Louisville.
-
Miltenyi Biotec B.V. & Co. KG Capacity Update April 2025: Cell & Gene Therapy
4/24/2025
In this presentation, Shaan Gareeb highlights the capabilities of our Cell Therapy Center of Excellence in San Jose, California, one of five global Miltenyi Bioindustry sites.
-
Andelyn Capacity Update April 2025: Cell & Gene Therapy
4/24/2025
Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.
-
SK pharmteco Capacity Update April 2025: Cell & Gene Therapy
4/24/2025
Our integrated expertise — from plasmid science to viral vector and cell therapy manufacturing — can accelerate and de-risk the development of your advanced therapies.
-
Advancing Cell & Gene Therapies To Patients
4/24/2025
Discover how we apply our expertise and know-how to efficiently advance your viral vector-based therapeutic through any phase, while enhancing quality and de-risking production.
-
Forge Biologics, A Member Of Ajinomoto Bio-Pharma Services, Capacity Update January 2025: Cell & Gene Therapy
1/30/2025
See how Forge’s dedicated 200,000 sq. ft. facility, proprietary technologies, and specialized services provide expert AAV manufacturing to empower developers from discovery to delivery and every step in between.
-
Andelyn Biosciences Capacity Update January 2025: Cell & Gene Therapy
1/30/2025
Here we introduce the structure and capabilities of our Laboratory Services group, a cornerstone of our commitment to excellence in pharmaceutical development.